Bharat Biotech, Thomas Jefferson University Pursue a Promising Vaccine Candidate Against COVID-19

coronavirus researchers

Hyderabad/ Philadelphia – May 20 2020: Global Leader and vaccine innovator Bharat Biotech and Thomas Jefferson University of Philadelphia have signed an exclusive deal to develop a new vaccine candidate for COVID-19 invented at Jefferson. The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins. This is in part because this vehicle or carrier vaccine is known to produce a strong immune response, and is approved for the whole population including children and pregnant women.

Infectious Diseases expert Professor Matthias Schnell’s lab developed the vaccine in January this year, and has recently completed preliminary tests in animal models. The vaccine showed a strong antibody response in mice receiving the vaccine.  The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in the next month.

“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” says Prof. Schnell - a coronavirus expert who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology, “We will be able to complete animal testing and move to phase 1 clinical trial rapidly” he adds.

Dr. Krishna Mohan, Chief Executive Officer of Bharat Biotech said, “In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform. We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases. Bharat Biotech is committed to global public health and will be involved in an end to end development of the vaccine including comprehensive clinical trials to achieve commercial licensure.”

Under the license agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine across the world excluding countries such as USA, Europe, Japan etc., where Jefferson continues to seek partners. With support from the Department of Biotechnology, Govt. of India, Bharat Biotech aims to get into human trials as soon as December 2020.

“Bharat Biotech is the world’s largest supplier of rabies vaccines, and has been at the forefront of creating breakthrough vaccines for several challenging diseases”, said Dr. Rose Ritts, Jefferson’s Innovation EVP, who led the negotiations with the assistance of Dr. Heather Rose, Innovation VP. “They are the right partner for Jefferson to accelerate this important project with urgency.” 

Of the 90 or so coronavirus vaccines in development, about 25% use an established vaccine to act as a “carrier” or vector for the target virus, in this case, the coronavirus SARS-COV-2 spike protein. The vector used in this new vaccine is a deactivated rabies vaccine that is known to produce a strong immune response, and that has been proven safe for all populations including children and pregnant women.

Not every vaccine produces the same level of the immune response. The rabies vaccine has been shown to generate a rigorous but safe immune reaction that confers life-long protection. “Since we know the immune system reacts to the rabies vaccine with a strong response when we add the coronavirus component, we expect to see that level of protection, and immune memory, carry over to the SARS-CoV-2 viral protein as well,” says Prof. Schnell.

Prof. Schnell’s prior research creating vaccines with this approach against two other strains of coronavirus (the 2003 SARS and 2012 MERS viruses), worked in this way, conferring strong immunity in animal models. 

“We are leveraging the properties of a very effective vaccine – one that provides life-long immunity against one of the biggest global threats of our time,” says Dr. Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs of Thomas Jefferson University, and Dean of its Sidney Kimmel Medical College. “Rather than go with an untested approach, we have a leg-up by using a vaccine that is safe, effective, and exceptionally good at creating a strong immune response – which is something not every vaccine can do.”

About Bharat Biotech:

Bharat Biotech has established an excellent track record of innovation with more than 100 global patents, a wide product portfolio of more than 16 products, registrations in more than 70 countries and WHO Pre-qualifications.

Having already delivered more than 4 billion doses of vaccines to the world, Bharat continues to innovate having developed vaccines for H1N1, Rotavirus, Japanese Encephalitis, Typhoid (world’s first conjugated typhoid vaccine) Chikungunya and Zika.

Our commitment to global social innovation programs and public private partnerships resulted in the introduction of path breaking WHO pre-qualified vaccines BIOPOLIO ®  ROTAVAC® and Typbar TCV®’ combatting polio, rotavirus, typhoid infections respectively. The recent acquisition of the Rabies vaccine facility, Chiron Behring from GSK has positioned Bharat as the largest Rabies vaccine manufacturer in the world.

About Prof. Schnell, Jefferson Vaccine Institute:

Prof. Matthias Schnell directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology.  Prof. Schnell’s work includes vaccines in development for other coronaviruses, as well as for Ebola, NIPAH, Lassa Fever, and Lyssa.

He has more than 120 peer-reviewed paper have been cited over 9000 times.  Dr. Schnell is the current Chair of the NIH VMD (Vaccines against Microbial Diseases) study section, and is on the editorial board of the Journal of Virology, the Journal of Vaccines, PLOS (Public Library of Science) ONE, PLOS Currents: Outbreaks and PLOS Pathogens.

Jefferson is seeking additional partners for clinical development in the developed world.

Media Contact:

Bharat Biotech: Sheela Panicker | +91 98498 09594 | enright@enrightpr.com

Jefferson: Edyta Zielinska | 215-955-7359 | edyta.zielinska@jefferson.edu.